Taiwan Liposome Ltd Quick Ratio (TLC) starting from the fourth quarter 2020 to fourth quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Taiwan Liposome Company Ltd   (NASDAQ: TLC)

Taiwan Liposome Ltd 's Quick Ratio

TLC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Taiwan Liposome Ltd 's Cash & cash equivalent, this led to improvement in Taiwan Liposome Ltd 's Quick Ratio to 11.66, above Taiwan Liposome Company Ltd average Quick Ratio.

Within Major Pharmaceutical Preparations industry 320 other companies have achieved higher Quick Ratio than Taiwan Liposome Ltd in fourth quarter 2020. While Quick Ratio total ranking in the fourth quarter 2020 has deteriorated compared to the prior quarter from 1146 to 1184.

Explain Quick Ratio?
How much Cash & cash equivalents TLC´s has?
What are TLC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TLC Quick Ratio (Dec 31 2020)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2019)
Q4
Y / Y Current Liabilities Change -84.07 % -7.18 % -7.18 % -7.18 % 1081.38 %
Y / Y Cash & cash equivalent Change 31.07 % 39.61 % 39.61 % 39.61 % 35.17 %
Quick Ratio MRQ 11.66 2.77 2.77 2.77 1.42
TLC's Total Ranking # 1184 # 1146 # 1153 # 1186 # 1197
Seq. Current Liabilities Change -76.25 % 0 % 0 % -32.92 % 38.37 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 31.07 % 6.51 %



Quick Ratio fourth quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 321
Healthcare Sector # 536
Overall Market # 1184


Quick Ratio Statistics
High Average Low
2.77 2.19 1.84
(Dec 31 2020)   (Dec 31 2019)




Financial Statements
Taiwan Liposome Ltd 's Current Liabilities $ 4 Millions Visit TLC's Balance sheet
Taiwan Liposome Ltd 's Cash & cash equivalent $ 48 Millions Visit TLC's Balance sheet
Source of TLC's Sales Visit TLC's Sales by Geography


Cumulative Taiwan Liposome Ltd 's Quick Ratio

TLC's Quick Ratio for the trailling 12 Months

TLC Quick Ratio

 (Dec 31 2020)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth -31.45 % 33.72 % 49.1 % 67.74 % 90.82 %
Y / Y Cash & cash equivalent TTM Growth 37.37 % 38.68 % 36.52 % 34.05 % 31.22 %
Quick Ratio TTM 3.42 2.32 2.11 1.9 1.71
Total Ranking TTM # 4516 # 4533 # 4543 # 4566 # 1090
Seq. Current Liabilities TTM Growth -27.91 % -1.69 % -1.67 % -1.64 % 40.63 %
Seq. Cash & cash equivalent TTM Growth 6.3 % 8.15 % 8.88 % 9.74 % 7.32 %

Quick ratio ranking by company, industry and sector >> Back to TLC Financial Strength Comparisons >> Go to Compare TLC Quick Ratio to its Competitors

On the trailing twelve months basis TLC Cash & cash equivalent grew by 31.07 % in Q4 2020 year on year, while Current Liabilities dropped to $4 millions, this led to increase in in Taiwan Liposome Ltd 's Quick Ratio to 3.42, above TLC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 470 other companies have achieved higher Quick Ratio than Taiwan Liposome Ltd . While Quick Ratio overall ranking has improved so far to 4516, from total ranking during the twelve months ending third quarter 2020 at 4533.

Explain Quick Ratio?
How much Cash & cash equivalents TLC´s has?
What are TLC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 471
Healthcare Sector # 910
Within the Market # 4516


trailing twelve months Quick Ratio Statistics
High Average Low
2.77 2.19 1.84
(Dec 31 2020)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Dec 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2020 MRQ Cash & cash equivalentDec 31 2020 MRQ Current Liabilities
Dyne Therapeutics Inc   31.49 $ 345.314  Millions$ 10.967  Millions
Sage Therapeutics Inc   31.24 $ 2,099.549  Millions$ 67.204  Millions
Arena Pharmaceuticals Inc   31.23 $ 1,104.041  Millions$ 35.351  Millions
Scorpius Holdings inc   30.57 $ 111.774  Millions$ 3.657  Millions
Zomedica Corp   30.56 $ 61.992  Millions$ 2.029  Millions
Repare Therapeutics Inc   30.30 $ 333.710  Millions$ 11.014  Millions
Damora Therapeutics Inc   29.39 $ 163.582  Millions$ 5.566  Millions
Cocrystal Pharma Inc   28.97 $ 33.060  Millions$ 1.141  Millions
Annexon Inc   28.79 $ 351.206  Millions$ 12.198  Millions
Akouos inc   28.76 $ 308.010  Millions$ 10.709  Millions
Essa Pharma inc   28.49 $ 74.501  Millions$ 2.615  Millions
Viela Bio Inc   28.47 $ 367.687  Millions$ 12.917  Millions
Rain Enhancement Technologies Holdco Inc   27.35 $ 58.885  Millions$ 2.153  Millions
Tff Pharmaceuticals Inc  27.20 $ 35.301  Millions$ 1.298  Millions
Connect Biopharma Holdings Limited  26.58 $ 154.803  Millions$ 5.823  Millions
Arvinas Inc   26.50 $ 688.531  Millions$ 25.982  Millions
Longboard Pharmaceuticals Inc   26.48 $ 55.316  Millions$ 2.089  Millions
Oncorus Inc   26.11 $ 130.305  Millions$ 4.991  Millions
Forte Biosciences Inc   26.01 $ 58.765  Millions$ 2.259  Millions
Dogwood Therapeutics inc   25.84 $ 29.795  Millions$ 1.153  Millions
Vera Therapeutics Inc   25.51 $ 53.740  Millions$ 2.107  Millions
Pandion Therapeutics Inc   24.83 $ 219.891  Millions$ 8.856  Millions
Neurogene Inc   24.41 $ 192.556  Millions$ 7.889  Millions
Kura Oncology Inc   24.34 $ 633.320  Millions$ 26.024  Millions
Rallybio Corporation  24.00 $ 140.233  Millions$ 5.843  Millions
Metacrine Inc   23.89 $ 96.176  Millions$ 4.026  Millions
Pliant Therapeutics Inc   23.87 $ 276.894  Millions$ 11.599  Millions
Annovis Bio Inc   23.62 $ 8.075  Millions$ 0.342  Millions
Lixte Biotechnology Holdings Inc   23.41 $ 5.069  Millions$ 0.217  Millions
Generation Bio Co   23.38 $ 262.327  Millions$ 11.220  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.